Via the Institute for Clinical and Economic Review:
The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document outlining its planned review of the comparative clinical effectiveness and value of emicizumab for prevention of bleeding in patients with hemophilia A who have inhibitors to coagulation factor VIII.
The scoping document will be open to public comment for three weeks until 5 p.m. Sept. 29. It will inform development of a report that will be subject to public deliberation during a March 2018 meeting of the New England Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees.
Click here to read the full press release on ICER’s website.
